...A. In GVHD, we have the launch of Niktimvo that is taking place now as we speak. B. The incidence is about 1 in 100,000 but the prevalence is at least 30 per 100,000 . C. Zooming in, in particular, on mutant CALR-positive ET, this represents around 30% also of our ET patient population. D. In this disease, these are pertinent points for you when you see the results later: a higher VAF tends to be the case for CALR patients compared to JAK2-positive ET, which is around 50% of the population. E. We have not had a new therapy for these patients since the approval of Anagrelide in 2005 in Europe. F. Anagrelide, interestingly, is also associated with VAF increases for CALR. G. At that time, her platelet count was 1,600-plus. H. The only data we really have for CALR, at the moment, is this increase in VAG with Anagrelide, which we know is associated with fibrosis. I. We recruited 180 patients. J. In this study, we showed that molecular response, which was just a 50% reduction in VAF -- but by...
